Amylin Receptor Agonist

Amylin Receptor Agonists (22):

Cat. No.	Product Name	Effect	Purity

HY-P10798

Eloralintide	Agonist	99.97%
Eloralintide is an amylin receptor (AMYR) activator and long-acting peptide. Eloralintide selectively activates amylin receptors. Eloralintide is modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide induces decreased appetite.Eloralintide reduces body weight. Eloralintide can be used for the research of obesity.

HY-185107

CTR/AMYR modulator-2	Agonist
CTR/AMYR modulator-2 (Example 107) is a receptor 3 for pancreatic amyloid peptide (bAMY3R) agonist, and its EC₅₀ for stimulating cAMP production in cells is ＜500 nM. CTR/AMYR modulator-2 is also a receptor for calcitonin (bCTR) agonist, with its EC₅₀ being ＜5000 nM. CTR/AMYR modulator-2 can be used for research on type 2 diabetes and obesity.

HY-P11610

KBP-089	Agonist
KBP-089 is a dual Amylin and Calcitonin Receptor agonist. KBP-089 reduces body weight, decreases adipose tissue mass and improves glucose tolerance in obese rats. KBP-089 also eliminates lipid accumulation in the liver and muscle, and ameliorates glycemic homeostasis and insulin sensitivity. KBP-089 is applicable to the research of diseases such as obesity and type 2 diabetes.

HY-P11274A

Zenagamtide sodium	Agonist	99.96%
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.

HY-P11245A

NN1213 acetate	Agonist	99.65%
NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC₅₀ values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity.

HY-P10956

Colulintide	Agonist	98.35%
Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity.

HY-P11320

Davalintide	Agonist	98.04%
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC₅₀ = 0.04 nM), calcitonin receptor (IC₅₀ = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC₅₀ = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC₅₀ = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes.

HY-P11274

Zenagamtide	Agonist
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.

HY-186104

AMYR/CTR agonist 1	Agonist
AMYR/CTR agonist 1 (Compound 195) is a pancreatic amylin receptor and calcitonin receptor (AMYR/CTR) agonist with EC₅₀ values for pancreatic amylin receptor and calcitonin receptor cAMP of 99.5 and 6.16 pM respectively. AMYR/CTR agonist 1 can be used in the research of diseases such as type 2 diabetes and obesity.

HY-185229B

rel-CTR/AMYR agonist-1	Agonist
rel-CTR/AMYR agonist-1 (Example 169) is an agonist of amylin and/or calcitonin receptor.

HY-P11586

San45	Agonist
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity.

HY-P11269

Lenbelintide	Agonist
Lenbelintide is a dual amylin/calcitonin receptor agonist. Lenbelintide can be studied in research on obesity.

HY-P11843

TPM004	Agonist
TPM004 is an ultralong-acting, nonaggregating dual amylin (AMY3R) and calcitonin receptor (CTR) agonist with EC₅₀ values of 0.5 and 0.7 pM. TPM004 induces weight loss, attenuates adiposity rebound, lowers glucose, and improves glucose homeostasis. TPM004 can be used for the research of obesity, diabetes.

HY-P11665

Batelintide	Agonist
Batelintide is a dual amylin/calcitonin receptor agonist with antidiabetic effects.

HY-P11584

KBP-066A	Agonist
KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity.

HY-P11830

UDA-6	Agonist
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity.

HY-P11245

NN1213	Agonist
NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC₅₀ values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity.

HY-P11587

BGM1812	Agonist
BGM1812 is a dual agonist of amylin (hAMY3R) (EC₅₀ = 0.627 nM) and CGRP Receptor (hCTR) (EC₅₀ = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity.

HY-P11629

KBP-336	Agonist
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.

HY-185229A

CTR/AMYR agonist-1 enantiomer	Agonist
CTR/AMYR agonist-1 enantiomer is an enantiomer of CTR/AMYR agonist-1 (HY-185229). CTR/AMYR agonist-1 is a CTR/AMYR agonist with EC₅₀ values of 0.56-6.9 nM. CTR/AMYR agonist-1 can be used for the research of metabolic disease.

Name
Email *

	Sorry, but the email address you supplied was invalid.